Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ATP13A3 divergent transcript (ATP13A3-DT, also known as LINC00884) is a long non-coding RNA gene identified on human chromosome 3 and affiliated with the lncRNA gene class. It is not a protein-coding gene and has no established role as a receptor, enzyme, transporter, or therapeutic target. Disease associations in database annotations include glioma susceptibility and arrhythmogenic right ventricular cardiomyopathy, but experimental evidence for these roles is limited or speculative. There are no approved or experimental drugs targeting ATP13A3-DT, nor is it recognized as a biomarker or involved in a known mechanism of action for therapeutics[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATP13A3 divergent transcript (ATP13A3-DT).